Skip to main content

Advertisement

SpringerLink
Log in

p53 and chemosensitivity in bladder cancer

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Urothelial carcinoma is the second most common genitourinary malignancy. Although the majority of patients present with superficial bladder tumors, there are several clinical problems, such as progression to invasive tumors, poor prognosis of invasive tumors, and chemosensitivity. Alterations in p53 represent one of the most common genetic events in patients with invasive urothelial carcinoma and are suggested to be linked to tumor progression, prognosis, and chemosensitivity. p53 possesses various functions, including induction of cell-cycle arrest, apoptosis, DNA repair, and antioxidants; it acts as a killer and a healer. In this article, we review the roles of p53 pathways in bladder carcinogenesis and findings from recent studies of ours and other groups, and we discuss the clinical significance of the abrogation of p53 pathways in the treatment of urothelial carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Messing EM (2002) Urothelial tumors of the urinary tract. In: Walsh PC (ed) Cambell’s urology, eighth edn. Sounders, Philadelphia, pp 2732–2784

    Google Scholar 

  2. Nishiyama H, Habuchi T, Watanabe J, et al. (2004) Clinical outcome of a large-scale multi-institutional retrospective study for locally advanced bladder cancer: a survey including 1131 patients treated during 1990–2000 in Japan. Eur Urol 45:176–181

    Article  PubMed  Google Scholar 

  3. Matsui Y, Nishiyama H, Watanabe J, et al. (2005) The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan. Int J Clin Oncol 10:133–138

    Article  PubMed  Google Scholar 

  4. Habuchi T, Marberger M, Droller MJ, et al. (2005) Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 66(6 Suppl 1):64–74

    Article  PubMed  Google Scholar 

  5. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331

    Article  PubMed  CAS  Google Scholar 

  6. Habuchi T, Ogawa O, Kakehi Y, et al. (1992) Allelic loss of chromosome 17p in urothelial cancer: strong association with invasive phenotype. J Urol 148:1595–1599

    PubMed  CAS  Google Scholar 

  7. Soussi T (2007) p53 alterations in human cancer: more questions than answers. Oncogene 26:2145–2156

    Article  PubMed  CAS  Google Scholar 

  8. Menendez D, Inga A, Jordan JJ, et al. (2007) Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Oncogene 26:2191–2201

    Article  PubMed  CAS  Google Scholar 

  9. Vousden KH (2006) Outcomes of p53 activation — spoilt for choice. J Cell Sci 119:5015–5020

    Article  PubMed  CAS  Google Scholar 

  10. Esrig D, Spruck CH, Nicholes PW et al. (1993) p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 143:1389–1397

    PubMed  CAS  Google Scholar 

  11. Mitra AP, Birkhahn M, Cote RJ (2007) p53 and retinoblastoma pathways in bladder cancer. World J Urol 25:563–571

    Article  PubMed  CAS  Google Scholar 

  12. Soussi T (2000) p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788

    PubMed  CAS  Google Scholar 

  13. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093

    Article  PubMed  CAS  Google Scholar 

  14. Livingstone LR, White A, Sprouse J, et al. (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935

    Article  PubMed  CAS  Google Scholar 

  15. el-Deiry WS (1998) Regulation of p53 downstream genes. Semin Cancer Biol 8:345–357

    Article  PubMed  CAS  Google Scholar 

  16. Chipuk JE, Green DR (2003) p53’s believe it or not: lessons on transcription-independent death. J Clin Immunol 23:355–361

    Article  PubMed  CAS  Google Scholar 

  17. Sengupta S, Harris CC (2005) p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 6:44–55

    Article  PubMed  CAS  Google Scholar 

  18. Gatz SA, Wiesmüller L (2006) p53 in recombination and repair. Cell Death Differ 13:1003–1016

    Article  PubMed  CAS  Google Scholar 

  19. Drane P, Bravard A, Bouvard V, et al. (2001) Reciprocal down-regulation of p53 and SOD2 gene expression — implication in p53 mediated apoptosis. Oncogene 20:430–439

    Article  PubMed  CAS  Google Scholar 

  20. Cheng WH, Zheng X, Quimby FR, et al. (2003) Low levels of glutathione peroxidase 1 activity in selenium-deficient mouse liver affect c-Jun N-terminal kinase activation and p53 phosphorylation on Ser-15 in pro-oxidant-induced aponecrosis. Biochem J 370:927–934

    Article  PubMed  CAS  Google Scholar 

  21. Matsui Y, Ueda S, Watanabe J, et al. (2007) Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species. Cancer Res 67:1212–1220

    Article  PubMed  CAS  Google Scholar 

  22. Sablina AA, Budanov AV, Ilyinskaya GV, et al. (2005) The antioxidant function of the p53 tumor suppressor. Nat Med 11:1306–1313

    Article  PubMed  CAS  Google Scholar 

  23. Gudkov AV (2002) Converting p53 from a killer into a healer. Nat Med 8:1196–1198

    Article  PubMed  CAS  Google Scholar 

  24. Helton ES, Chen X (2007) p53 modulation of the DNA damage response. J Cell Biochem 100:883–896

    Article  PubMed  CAS  Google Scholar 

  25. Mitra AP, Datar RH, Cote RJ (2006) Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 24:5552–5564

    Article  PubMed  CAS  Google Scholar 

  26. Knowles MA (2006) Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27:361–373

    Article  PubMed  CAS  Google Scholar 

  27. Bakkar AA, Wallerand H, Radvanyi F, et al. (2003) FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108–8112

    PubMed  CAS  Google Scholar 

  28. Petitjean A, Achatz MI, Borresen-Dale AL, et al. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–2165

    Article  PubMed  CAS  Google Scholar 

  29. Olivier M, Eeles R, Hollstein M, et al. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607–614

    Article  PubMed  CAS  Google Scholar 

  30. Kato S, Han SY, Liu W, et al. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci USA 100:8424–8429

    Article  PubMed  CAS  Google Scholar 

  31. Olive KP, Tuveson DA, Ruhe ZC, et al. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847–860

    Article  PubMed  CAS  Google Scholar 

  32. Okuda E, Osugi H, Morimura K, et al. (2001) Detection of p53 gene mutations in human esophageal squamous cell carcinomas using a p53 yeast functional assay: possible difference in esophageal carcinogenesis between the young and the elderly group. Clin Cancer Res 7:600–606

    PubMed  CAS  Google Scholar 

  33. Hashimoto T, Tokuchi Y, Hayashi M, et al. (1999) p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 59:5572–5577

    PubMed  CAS  Google Scholar 

  34. Watanabe J, Nishiyama H, Okubo K, et al. (2004) Clinical evaluation of p53 mutations in urothelial carcinoma by IHC and FASAY. Urology 63:989–993

    Article  PubMed  Google Scholar 

  35. Stein JP, Grossfeld GD, Ginsberg DA, et al. (1998) Prognostic markers in bladder cancer: a contemporary review of literature. J Urol 160:645–659

    Article  PubMed  CAS  Google Scholar 

  36. Esrig D, Elmajian D, Groshen S, et al. (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259–1264

    Article  PubMed  CAS  Google Scholar 

  37. Sjögren S, Inganäs M, Norberg T, et al. (1996) The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst 88:173–182

    Article  PubMed  Google Scholar 

  38. Abdel-Fattah R, Challen C, Griffiths TR, et al. (1998) Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. Br J Cancer 77:2230–2238

    PubMed  CAS  Google Scholar 

  39. Tada M, Iggo RD, Ishii N, et al. (1996) Clonality and stability of the p53 gene in human astrocytic tumor cells: quantitative analysis of p53 gene mutations by yeast functional assay. Int J Cancer 67:447–450

    Article  PubMed  CAS  Google Scholar 

  40. Lu ML, Wikman F, Orntoft TF, et al. (2002) Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 8:171–179

    PubMed  CAS  Google Scholar 

  41. Chatterjee SJ, Datar R, Youssefzadeh D, et al. (2004) Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22:1007–1013

    Article  PubMed  CAS  Google Scholar 

  42. Shariat SF, Zlotta AR, Ashfaq R, et al. (2007) Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 20:445–459

    Article  PubMed  CAS  Google Scholar 

  43. Cote RJ, Esrig D, Groshen S, et al. (1997) P53 and treatment of bladder cancer. Nature 385:123–124

    Article  PubMed  CAS  Google Scholar 

  44. Qureshi KN, Griffiths TRL, Robinson MC, et al. (1999) TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res 5:3500–3507

    PubMed  CAS  Google Scholar 

  45. Cote RJ, Datar RH (2003) Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Crit Rev Oncol Hematol 46(Suppl):S67–S83

    Article  PubMed  Google Scholar 

  46. Weller M (1998) Predicting response to cancer chemotherapy: the role of p53. Cell Tissue Res 292:435–445

    Article  PubMed  CAS  Google Scholar 

  47. Martinez LA, Yang J, Vazquez ES, et al. (2002) p21 modulates threshold of apoptosis induced by DNA-damage and growth factor withdrawal in prostate cancer cells. Carcinogenesis 23:1289–1296

    Article  PubMed  CAS  Google Scholar 

  48. Watanabe J, Nishiyama H, Matsui Y, et al. (2006) Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene 25:2500–2508

    Article  PubMed  CAS  Google Scholar 

  49. Matsui Y, Watanabe J, Ikegawa M, et al. (2008) Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53. Oncogene. 2008 Apr 7. [Epub ahead of print]

  50. Weiss RH, Marshall D, Howard L, et al. (2003) Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxy-nucleotide to p21 (Waf1/Cip1). Cancer Lett 189:39–48

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan

    Hiroyuki Nishiyama, Jun Watanabe & Osamu Ogawa

Authors
  1. Hiroyuki Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jun Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Osamu Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Nishiyama.

About this article

Cite this article

Nishiyama, H., Watanabe, J. & Ogawa, O. p53 and chemosensitivity in bladder cancer. Int J Clin Oncol 13, 282–286 (2008). https://doi.org/10.1007/s10147-008-0815-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0815-x

Key words

Search

Navigation